S&P 500   4,970.63 (-0.81%)
DOW   37,864.79 (+0.24%)
QQQ   415.91 (-1.77%)
AAPL   164.41 (-1.57%)
MSFT   398.56 (-1.41%)
META   481.27 (-4.09%)
GOOGL   153.05 (-1.90%)
AMZN   174.63 (-2.56%)
TSLA   148.33 (-1.07%)
NVDA   805.15 (-4.91%)
AMD   148.11 (-4.49%)
NIO   3.81 (-4.75%)
BABA   68.48 (-0.58%)
T   16.30 (-0.18%)
F   12.08 (+0.17%)
MU   107.11 (-4.31%)
GE   147.70 (-3.43%)
CGC   7.88 (+0.64%)
DIS   111.50 (-0.83%)
AMC   3.20 (+9.59%)
PFE   25.81 (+1.65%)
PYPL   61.85 (-0.40%)
XOM   119.85 (+1.12%)
S&P 500   4,970.63 (-0.81%)
DOW   37,864.79 (+0.24%)
QQQ   415.91 (-1.77%)
AAPL   164.41 (-1.57%)
MSFT   398.56 (-1.41%)
META   481.27 (-4.09%)
GOOGL   153.05 (-1.90%)
AMZN   174.63 (-2.56%)
TSLA   148.33 (-1.07%)
NVDA   805.15 (-4.91%)
AMD   148.11 (-4.49%)
NIO   3.81 (-4.75%)
BABA   68.48 (-0.58%)
T   16.30 (-0.18%)
F   12.08 (+0.17%)
MU   107.11 (-4.31%)
GE   147.70 (-3.43%)
CGC   7.88 (+0.64%)
DIS   111.50 (-0.83%)
AMC   3.20 (+9.59%)
PFE   25.81 (+1.65%)
PYPL   61.85 (-0.40%)
XOM   119.85 (+1.12%)
S&P 500   4,970.63 (-0.81%)
DOW   37,864.79 (+0.24%)
QQQ   415.91 (-1.77%)
AAPL   164.41 (-1.57%)
MSFT   398.56 (-1.41%)
META   481.27 (-4.09%)
GOOGL   153.05 (-1.90%)
AMZN   174.63 (-2.56%)
TSLA   148.33 (-1.07%)
NVDA   805.15 (-4.91%)
AMD   148.11 (-4.49%)
NIO   3.81 (-4.75%)
BABA   68.48 (-0.58%)
T   16.30 (-0.18%)
F   12.08 (+0.17%)
MU   107.11 (-4.31%)
GE   147.70 (-3.43%)
CGC   7.88 (+0.64%)
DIS   111.50 (-0.83%)
AMC   3.20 (+9.59%)
PFE   25.81 (+1.65%)
PYPL   61.85 (-0.40%)
XOM   119.85 (+1.12%)
S&P 500   4,970.63 (-0.81%)
DOW   37,864.79 (+0.24%)
QQQ   415.91 (-1.77%)
AAPL   164.41 (-1.57%)
MSFT   398.56 (-1.41%)
META   481.27 (-4.09%)
GOOGL   153.05 (-1.90%)
AMZN   174.63 (-2.56%)
TSLA   148.33 (-1.07%)
NVDA   805.15 (-4.91%)
AMD   148.11 (-4.49%)
NIO   3.81 (-4.75%)
BABA   68.48 (-0.58%)
T   16.30 (-0.18%)
F   12.08 (+0.17%)
MU   107.11 (-4.31%)
GE   147.70 (-3.43%)
CGC   7.88 (+0.64%)
DIS   111.50 (-0.83%)
AMC   3.20 (+9.59%)
PFE   25.81 (+1.65%)
PYPL   61.85 (-0.40%)
XOM   119.85 (+1.12%)
Free Trial
NASDAQ:CYTR

LadRx (CYTR) Stock Price, News & Analysis

→ Bitcoin Rockets To Record High But Buy THIS Instead (From Paradigm Press) (Ad)
Free CYTR Stock Alerts
Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
N/A
50-Day Range
$0.09
▼
$0.10
52-Week Range
N/A
Volume
4,000 shs
Average Volume
99,706 shs
Market Capitalization
$4.14 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock Analysis
Stock Analysis
CYTR stock logo

About LadRx Stock (NASDAQ:CYTR)

LadRx Corp. is a biopharmaceutical research and development company, which engages in the discovery, research, and clinical development of novel anti-cancer drug candidates. It focuses on developing the Linker Activated Drug Release (LADR) technology platform, a discovery engine to help create a pipeline of anti-cancer molecules that will avoid unacceptable systemic toxicity while delivering highly potent agents directly to the tumor. The company was founded in 1985 and is headquartered in Los Angeles, CA.

CYTR Stock News Headlines

May 17, 2023 | investing.com
LadRx (LADX) Earnings Dates & Reports
March 29, 2023 | stockhouse.com
LadRx Highlights Patent Issued for Its LADR Technology
April 19, 2024 | DTI (Ad)
With the “Bitcoin Loophole” you can supercharge the gains by 10x or more
Thanks to this newly discovered Bitcoin Loophole, you can now trade Bitcoin in any regular brokerage account… And not only that… you can use it to supercharge the gains of Bitcoin by 10x or more! You see, thanks to one unique investor's brand new discovery - anyone with a regular brokerage account can now tap into the most explosive asset in history. That means you can skip the hassle of opening a Coinbase account… Bypass the fees and hard-to-remember passwords…
October 5, 2022 | finance.yahoo.com
LadRx Corporation Announces OTCQB Ticker Change to LADX
September 23, 2022 | finance.yahoo.com
CytRx Corporation Relaunches as LadRx Corporation
September 8, 2022 | seekingalpha.com
European patent office awards CytRx patent for LADR platform
September 7, 2022 | finance.yahoo.com
European Patent Office Awards CytRx Key Patent
August 3, 2022 | marketwatch.com
Temperature Data logger Market Size: Market Growth at a CAGR of 3.64% to Outstrip USD 1364.75 Million by 2028
April 19, 2024 | DTI (Ad)
This company has increased its dividend every year for 54 years
There are three basic steps to building the Ultimate Dividend Portfolio. Step #1 is to Get The High Yields! So an index fund like the SPY, paying only 1.5% a year, isn’t going to cut it. But a company like Altria Group (MO) will.
August 2, 2022 | thestreet.com
Whiplash: S&P Veers to All-Time High Before Crashing
May 19, 2022 | finance.yahoo.com
CytRx Announces Distribution of Series D Preferred Stock to Holders of Its Common Stock
May 18, 2022 | marketwatch.com
Kinase Inhibitors Market Report [2022]- Historical, Current, and Projected Size, in terms of value
See More Headlines
Receive CYTR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for LadRx and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Manufacturing
Industry
N/A
Sub-Industry
N/A
Current Symbol
NASDAQ:CYTR
CUSIP
N/A
CIK
N/A
Web
www.cytrx.com
Phone
(310) 826-5648
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
45,037,000
Free Float
N/A
Market Cap
$4.14 million
Optionable
Not Optionable
Beta
N/A
Ten Starter Stocks For Beginners to Buy Now Cover
Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

  • Stephen Snowdy
    Chief Executive Officer
  • John Y. Caloz
    Chief Financial Officer, Treasurer & Senior VP
  • Felix Kratz
    Vice President-Drug Discovery
  • Cristina Newman
    Secretary

Key Competitors

View All Competitors

This page (NASDAQ:CYTR) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners
Healthcare Takes A Big Step Forward With The Help Of AI
The Bull Report
The Best AI Stock to Own in the World Today is Trading for Just $25
Banyan Hill Publishing
The “Perfect Storm” for Gold
Gold Safe Exchange
Biden’s $374B Giveaway Into This Sector
DTI
The #1 Crypto for 2024
InvestorPlace
He Is Giving Away Bitcoin
Crypto Swap Profits
Urgent alert: open this for a huge profit potential
Timothy Sykes
1970’s computer coder issues shocking A.I. warning
TradeSmith